A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.
Non-small cell lung cancer is the most common type of lung cancer. While standard treatments help many people, doctors are constantly searching for newer, more effective options. This Phase 2 trial is investigating an experimental medicine called petosemtamab. In this study, petosemtamab is given alongside pembrolizumab (brand name Keytruda), a medicine already used to treat various cancers by helping the immune system attack cancer cells. Researchers want to see if using both drugs together helps shrink lung tumours or stop them from growing, while carefully checking for any unwanted side effects. Participants receive the treatments as an infusion through a drip in a hospital clinic. Throughout the study, doctors keep a close eye on patient health using blood tests and imaging scans. The findings will help determine whether this combination could become a valuable future treatment.
At a glance
What is this study about?
Lung cancer affects thousands of people in the UK each year, with non-small cell lung cancer being the most common form. Over recent years, immunotherapy medicines—treatments that empower the body's natural defences to fight tumours—have improved outcomes. However, not all tumours respond to standard therapies, and some become resistant over time. Finding new drug combinations is crucial to giving people more treatment choices.
This Phase 2 study explores whether adding a new drug, petosemtamab, to pembrolizumab can provide better results than standard options alone. Pembrolizumab works by releasing the brakes on the immune system, allowing it to recognise and attack cancer cells. Petosemtamab is designed to target specific proteins on cancer cells to stop them growing and multiplying. Researchers hope the two drugs together will have a stronger effect against the cancer.
The main aim is to evaluate whether tumours shrink, how long the positive response lasts, and whether the treatment helps keep the cancer stable over time. Doctors will also carefully track any side effects to ensure the combination is safe and manageable for patients in day-to-day life.
Key takeaways
- Tests a new combination of petosemtamab and pembrolizumab for non-small cell lung cancer.
- Open to adults aged 18 and older in acceptable overall health.
- Aims to find out if the combined medicines shrink tumours and can be used safely.
- Involves regular hospital clinic visits for infusions, blood tests, and scans.
- Participation is entirely voluntary, and you can withdraw at any time.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with non-small cell lung cancer. Both men and women can take part.
Because this is a specialised study, patients will need to meet certain general health criteria. For example, your heart, kidneys, and liver must be working well enough to safely process the trial medications, and you must be well enough to travel for clinic appointments.
People with certain other active medical conditions, severe infections, or specific previous cancer treatments may not be able to join. The hospital study team will carry out a thorough medical review to decide if the trial is safe and suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with non-small cell lung cancer.
- I am well enough to attend regular hospital appointments for infusions and scans.
- I do not have severe unmanaged heart, kidney, or liver problems.
- I am open to receiving trial treatments through an intravenous drip.
What does participation involve?
Taking part involves receiving both petosemtamab and pembrolizumab as intravenous infusions, meaning they are given through a small tube into a vein at a hospital clinic. Before treatment starts, you will have baseline tests, including blood tests, physical examinations, and scans (such as CT scans) to measure your cancer. During the study, you will visit the clinic regularly for treatment cycles and monitoring. Scans will be repeated every few weeks or months to see how your tumour is responding. The trial will continue as long as the treatment is helping and side effects remain manageable, often lasting several months to a couple of years, followed by regular check-ins to monitor your long-term health.
Potential risks and benefits
Locations (6)
- —UnverifiedSpain
- —UnverifiedBelgium
- —UnverifiedNetherlands
- —UnverifiedPoland
- —UnverifiedItaly
- —UnverifiedFrance
Common questions
What is the difference between petosemtamab and pembrolizumab?
Pembrolizumab (Keytruda) is an approved immunotherapy that helps your immune system attack cancer cells. Petosemtamab is an experimental drug designed to block specific signals that help tumours grow.
How are the medicines given?
Both medicines are given as a liquid infusion through a drip directly into a vein at the hospital day unit.
Will I have to pay to take part?
No. The trial medication, extra tests, and hospital appointments related to the study are provided free of charge, and travel expenses may be covered.
Can I leave the study if I change my mind?
Yes. You have the right to withdraw from the trial at any time, for any reason, without your future medical care being affected.
What happens if the treatment stops working for me?
If your scans show the cancer is growing or if side effects become too severe, the trial team will stop the study treatment and discuss other suitable care options with you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.